Mark Alles
Director/Board Member at BIOMARIN PHARMACEUTICAL INC.
Net worth: 1 M $ as of 31/03/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jonathan Biller | M | 61 |
Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | 9 years |
Christopher Bahl | M | - |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
John F. Chin | M | 58 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 26 years |
David Licata | M | - |
TORL Biotherapeutics LLC
TORL Biotherapeutics LLC BiotechnologyHealth Technology TORL Biotherapeutics LLC is a clinical-stage biopharmaceutical company based in Culver City, CA. TORL Biotherapeutics LLC is focused on developing new antibodies, including monoclonal antibodies (mAbs) and drug conjugates (ADCs), to transform the lives of patients with various types of cancer. TORL has a strategic partnership with the Slamon Research Lab and has exclusive rights to a program of biologics-based drugs for novel cancer targets. The company's lead program, TORL-1-23, is an ADC directed towards cldn6 for patients with multiple cancers. In addition to this, TORL has four other clinical-stage antibody programs and is building a pipeline of novel ADCs and mAbs for cancers with high unmet medical needs. The company was founded by David Licata, and the CEO is Mark J. Alles. | - |
Jean-Jacques Bienaimé | M | 70 | 19 years | |
John McKearn | M | 70 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
Barbara Bodem | F | 56 | 3 years | |
Peter Kellogg | M | 67 | 6 years | |
Kumar Srinivasan | M | 59 |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | 1 years |
Katherine Reynolds Kelly | F | 48 | 5 years | |
Alexander Hardy | M | 56 | 1 years | |
David Elkins | M | 55 | 6 years | |
Conley Chee | M | 54 | 3 years | |
Sandra Ramos-Alves | F | - | 2 years | |
Randy Meier | M | 65 | 18 years | |
Noah Beerman | M | 62 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 1 years |
Philip Lo Scalzo | M | - | 17 years | |
Jing Qian | F | 48 | 4 years | |
Sheng Tang | M | 40 | 4 years | |
Elizabeth Anderson | F | 66 | 5 years | |
Willard Dere | M | 70 | 8 years | |
Adam Levy | M | - | 3 years | |
Natalie Mount | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | 2 years |
Andrew Oh | M | 53 | 2 years | |
Athena Countouriotis | M | 52 | 1 years | |
Karen Hunady | F | - | 2 years | |
Drew Dennison | M | - |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
Rafael Fonseca | M | 57 | 1 years | |
Dennis Joseph Slamon | M | 75 | 10 years | |
Matthew Cooper | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
Matt Roden | M | 53 | 5 years | |
Elaine Heron | M | 76 | 22 years | |
V. Lawlis | M | 72 | 17 years | |
May Kin Ho | M | 71 | 3 years | |
Deborah Dunsire | M | 61 | 3 years | |
Tim Tyson | M | 71 | 2 years | |
Brian Mueller | M | 50 | 22 years | |
S. Gail Eckhardt | M | 66 | 4 years | |
George Davis | M | 53 | 20 years | |
Mark Enyedy | M | 60 | 1 years | |
Robert Hombach | M | 58 | 7 years | |
Stuart Bunting | M | - | 16 years | |
Jeff Ajer | M | 61 | 19 years | |
Kenneth Anderson | M | 72 |
Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | 16 years |
P. Joseph Campisi | M | - | 5 years | |
David Pyott | M | 70 | 8 years | |
C. Guyer | M | 62 | 4 years | |
Ann Li Lee | M | 63 | 6 years | |
Jason Haas | M | 56 | 3 years | |
Humaira Serajuddin | F | - | 2 years | |
Erin Burkhart | F | 45 | 2 years | |
Ganesh Vedantham | M | - | 3 years | |
Brian Sun | M | 40 | 2 years | |
Kimberly McCutcheon Jablonski | F | - | 2 years | |
Xiao-Jing Zhang | M | - | 2 years | |
Bruce Evans | M | 64 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
Mark Lewis | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
Elena A. Prokupets | M | - |
Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | - |
Bruce Downey | M | 76 |
Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | - |
Henry Fuchs | M | 66 | 15 years | |
Jim Jeffs | M | 71 |
TORL Biotherapeutics LLC
TORL Biotherapeutics LLC BiotechnologyHealth Technology TORL Biotherapeutics LLC is a clinical-stage biopharmaceutical company based in Culver City, CA. TORL Biotherapeutics LLC is focused on developing new antibodies, including monoclonal antibodies (mAbs) and drug conjugates (ADCs), to transform the lives of patients with various types of cancer. TORL has a strategic partnership with the Slamon Research Lab and has exclusive rights to a program of biologics-based drugs for novel cancer targets. The company's lead program, TORL-1-23, is an ADC directed towards cldn6 for patients with multiple cancers. In addition to this, TORL has four other clinical-stage antibody programs and is building a pipeline of novel ADCs and mAbs for cancers with high unmet medical needs. The company was founded by David Licata, and the CEO is Mark J. Alles. | 4 years |
Kevin Kaijun Li | M | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | - |
Jeffrey Galik | M | - | 5 years | |
Todd Kaloudis | M | - |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 2 years |
Eduardo Von Pervieux | M | - | 16 years | |
Traci McCarty | F | - | - | |
Amy Wireman | F | - | 11 years | |
Nicole Keith | F | - | 9 years | |
Bobby Sandage | M | 70 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
Christopher Williams | M | - | - | |
Malcolm Salter | M | 84 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 2 years |
Kevin Eggan | M | - | 4 years | |
Dave Jacoby | M | - | 8 years | |
Brad Glasscock | M | - | 12 years | |
Brinda Balakrishnan | M | 44 | 8 years | |
Sophia Park | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jacqualyn Fouse | M | 62 | 7 years | |
Sol Barer | M | 76 | 25 years | |
Robert Hugin | M | 69 | 19 years | |
Thomas Daniel | M | 69 | 10 years | |
Adora Ndu | M | 43 | 5 years | |
Kevin Patrick Lynch | M | 59 | 10 years | |
Garry Nicholson | M | 69 | 2 years | |
Scott Smith | M | 61 | 10 years | |
Timothy J. Smith | M | - | - | |
Gerald Quirk | M | 56 | 6 years | |
Perry Karsen | M | 69 | 9 years | |
Michael Bonney | M | 65 | 5 years | |
Annette C. North | F | 58 | 3 years | |
John Kelley | M | 70 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 4 years |
Amir Nashat | M | 51 | 8 years | |
Simeon George | M | 46 | 5 years | |
Vicki Sato | M | 75 | 6 years | |
Phillip Sharp | M | 79 | 10 years | |
Timothy L. Miller | M | 67 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 18 years |
Paolo Tombesi | M | 60 | 1 years | |
Julia Haller | M | 69 | - | |
Carol Gallagher | M | 59 | 3 years | |
Clarence Machado | M | 60 | 3 years | |
Dana Hu-Lowe | M | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 96 | 96.00% |
China | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Alles
- Personal Network